- Oculis Holding AG (Nasdaq: OCS) will participate in key investor conferences in May 2025.
- The company's CEO and CFO will present at four major events, providing updates and engaging with investors.
- Webcast links for presentations will be available on the Oculis website.
Oculis Holding AG (OCS), a leading biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, has announced its participation in several upcoming investor conferences throughout May 2025. As the company aims to enhance its visibility within the investor community, it will present at Bio€quity Europe in Bruges, the Bank of America Healthcare Conference in Las Vegas, H.C. Wainwright Annual BioConnect at Nasdaq in New York, and the Stifel Virtual Ophthalmology Forum.
CEO Riad Sherif and CFO Sylvia Cheung of Oculis (OCS) will lead the presentations, providing updates and insights into the company's innovative pipeline, which includes promising candidates such as OCS-01 for diabetic macular edema and Privosegtor (OCS-05) for acute optic neuritis. During these conferences, investors will have the opportunity for one-on-one meetings with the company’s leadership.
Webcast links for these presentations will be accessible on the Oculis website, particularly on the Events & Presentation page under the Investors & Media section. Investors interested in participating in one-on-one meetings are encouraged to contact the representatives at the respective sponsoring institutions to make arrangements.
